AcuityMD Raises $80M in Series C Funding Led by StepStone Group

The raise brought the total amount to $160M to date. The company is valued at $955M. The company plans to use the funds to improve its agentic AI tools for business users like sales teams, leaders, and marketers, strengthen its MedTech data model, and expand its platform.

MedTech companies are under pressure not only to launch new products but also to grow market share in a fast-changing environment. Changes such as portfolio updates, hospital consolidations, shifting regulations, and reimbursement rules can quickly reshape the market, making it hard for sales teams and leaders to keep up.

AcuityMD was built to solve a key problem: the insights MedTech companies need are spread across many sources like claims data, FDA filings, government records, and market signals, making them hard to combine. AcuityMD brings all this information together into one system that maps doctors, hospitals, procedures, payments, and their relationships. It also connects this data to each company’s internal information, such as contracts, products, territories, and CRM activity, creating a single, always-updated view of the healthcare market for faster, better decisions.

AcuityAI, now in open beta, is built on this foundation. It combines AcuityMD’s data system, a company’s business context, and each sales rep’s situation to provide insights that general AI tools cannot match. This helps reps spend less time planning and more time meeting the right doctors with the right information to win more business.

Read More:Humble Raises $24M in Seed Funding Led by Eclipse

“AI will transform MedTech, but only with the right context, deeply embedded in the workflows where decisions are made. AcuityMD is that context layer, serving the rep in the field, the commercial leader planning territories, and the teams launching the next generation of innovation. I'm grateful to the hundreds of customers who have helped shape our platform,” concluded Mike Monovoukas, CEO and co founder of AcuityMD. “This funding accelerates our shared mission of accelerating the adoption of cutting edge medical technologies.”

"AcuityAI has given our commercial team sharper answers, faster,” said Mark Edwards, senior director of sales operations at Kuros Biosciences. “Insights that used to take hours are now surfaced right when our reps need them, leading to richer conversations and opportunities we might otherwise have missed. One of our sales leaders asked AcuityAI for intel on a new national contract with a large health system, and quickly had a full business plan: where to go, which surgeons to prioritize and more context than he could get spending hours on Google.”

“AcuityMD is scaling rapidly while continuing to invest thoughtfully in its people and platform,” said Hunter Somerville, Partner at StepStone Group. “The depth of the company’s data provides a meaningful advantage, and as AI capabilities continue to advance, that foundation becomes more valuable. We also see significant opportunities for AcuityMD to benefit the broader MedTech organization beyond commercial, reinforcing our decision to deepen our commitment.”

About AcuityMD

Founded by Michael Monovoukas, Lee Smith, and Robert Coe, AcuityMD is an AI platform used by more than 400 MedTech companies, including 16 of the top 20. It helps commercial teams find target markets, identify opportunities and grow their business. By combining real world healthcare data with AI insights, AcuityMD helps companies of all sizes understand where and how to sell more quickly.

Read More:Qualitate Raises $7M in Seed Funding Led by IA Ventures